Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 2 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Certain Clinical Factors Tied to Poor Response to Biologics for Psoriasis
MedPage Today· 2 days agoPrevious exposure to biologics, higher BMI, smoking all negatively linked to response
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 2 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
The Gut-Skin Axis May Be the Key to Healthy, Glowing Skin
First for Women via Yahoo News· 6 days agoWhether we’re talking about brain fog, weight loss or the immune system, lately it seems it all...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 17 hours agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of “Moderate Buy” by Analysts
ETF DAILY NEWS· 4 hours agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, Marketbeat Ratings ...
Why Is My Skin So Itchy?
Verywell Health via Yahoo News· 2 days agoPruritus, or itchy skin, is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. It can be painful or...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 11 hours agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 1 day agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts
ETF DAILY NEWS· 5 hours agoAnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports ...